EP
CRDF icon

Essential Partners’s Cardiff Oncology CRDF Stock Holding History

Essential Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71K Sell
2,085
-482
-19% -$765 ﹤0.01% 1846
2026
Q1 		$4.16K Buy
+2,567
New +$5.27K ﹤0.01% 1665

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Essential Partners's CRDF Position: Q2 2026 in Review

Essential Partners reduced its Cardiff Oncology (CRDF) stake by 19% in Q2 2026, selling an estimated $765 and leaving 2,085 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

Essential Partners first reported a position in CRDF in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.16K in Q1 2026. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Essential Partners held 2,085 shares of Cardiff Oncology worth $2.71K as of Q2 2026.
  • Essential Partners sold 482 Cardiff Oncology shares in Q2 2026, an estimated $765.
  • Cardiff Oncology made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1846 holding.
  • Essential Partners first reported a position in Cardiff Oncology in Q1 2026 and has held it in 2 quarters since.
  • Essential Partners's Cardiff Oncology position peaked at $4.16K in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.